Liver problems with Abbott Laboratories Inc.’s discontinued attention deficit drug Cylert and other generic versions are too dangerous for the U.S. market, the Food and Drug Administration said on Monday.

“The agency has concluded that the overall risk of liver toxicity from Cylert and generic pemoline products outweighs the benefits of this drug,” the FDA said in a warning posted on its Web site.

In March, Abbott said it would no longer make the drug due to declining sales, but consumer advocates had argued it was too dangerous to be sold.

 


Comments


View Comments / Leave a Comment

This post currently has 2 comments.
You can read the comments or leave your own thoughts.


    Last reviewed: By John M. Grohol, Psy.D. on 24 Oct 2005
    Published on PsychCentral.com. All rights reserved.

APA Reference
Grohol, J. (2005). Discontinued ADD drug too risky: FDA. Psych Central. Retrieved on September 15, 2014, from http://psychcentral.com/blog/archives/2005/10/24/discontinued-add-drug-too-risky-fda/

 

Recent Comments
  • forrest: This very good information. As i read this i was tripping out because this is how my mother acts all the...
  • R :): I can not beleive it took me this long to figure out i might not be alone in this! I’m 22 and since i...
  • Don't want to use my name: Hi I have been married for 47 years and am in a very emotionally abusive relationship. We...
  • Valerie S.: I appreciate you mentioning the fake funerals; I had never even heard of that prior to reading this...
  • Matt: I have manic and ADHD issues more than anything and in my experiences, social workers had always been the one...
Subscribe to Our Weekly Newsletter


Find a Therapist
Enter ZIP or postal code